Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Duda

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Frontiers in Immunology|August 25, 2023
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activationGuo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, et al.
Frontiers in Immunology|October 11, 2023
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activationGuo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, et al.
Neurology|February 4, 2009
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionB O Khatri, S Man, G Giovannoni, et al.
The Lancet. Rheumatology|March 16, 2023
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trialAndrew L Mammen, Anthony A Amato, Mazen M Dimachkie, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Therapeutic Advances in Neurological Disorders|April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyJames F Howard, Saskia Bresch, Constantine Farmakidis, et al.
Pediatrics|March 17, 2010
Clinical genetic testing for patients with autism spectrum disordersYiping Shen, Kira A Dies, Ingrid A Holm, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
JAMA Network Open|February 17, 2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialSabrina Paganoni, Christina N Fournier, Eric A Macklin, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Frontiers in Immunology|August 25, 2023
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activationGuo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, et al.
Frontiers in Immunology|October 11, 2023
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activationGuo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, et al.
Neurology|February 4, 2009
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionB O Khatri, S Man, G Giovannoni, et al.
The Lancet. Rheumatology|March 16, 2023
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trialAndrew L Mammen, Anthony A Amato, Mazen M Dimachkie, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 studyJames F Howard, Saskia Bresch, Angela Genge, et al.
Therapeutic Advances in Neurological Disorders|April 19, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension studyJames F Howard, Saskia Bresch, Constantine Farmakidis, et al.
Pediatrics|March 17, 2010
Clinical genetic testing for patients with autism spectrum disordersYiping Shen, Kira A Dies, Ingrid A Holm, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
JAMA Network Open|February 17, 2025
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialSabrina Paganoni, Christina N Fournier, Eric A Macklin, et al.
Pageof 4